A carregar...
Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells
Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its...
Na minha lista:
| Publicado no: | Medchemcomm |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Royal Society of Chemistry
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6071735/ https://ncbi.nlm.nih.gov/pubmed/30108778 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c6md00643d |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|